Episode 139: Follicular Lymphoma Series, Pt 4...

This week we kick off a brand-new series on pancreatic cancer, starting with the fundamentals. Using the case of a 68-year-old man with painless jaundice, weight loss, and new-onset diabetes, we cover the epidemiology and sobering survival statistics of pancreatic ductal adenocar ...  Afficher plus

This week we wrap up our two-part CLL update by turning to relapsed and refractory disease. We pick up with the 68-year-old man from Part 1, now a year out from frontline therapy and showing signs of relapse. We cover when relapse actually needs treatment, the history of BTK inhi ...  Afficher plus

This week’s episode will be focusing on one of the Non-Hodgkin Lymphomas: Follicular Lymphoma. We will go over the important details on diagnostic criteria, indications for treatment and treatment options.

In this week's episode, we’ll learn more about mechanisms of primary resistance to BCMA-targeted bispecific T-cell engagers in relapsed/refractory multiple myeloma, the effects of emapalumab therapy on outcomes in patients with pediatric hemophagocytic lymphohistiocytosis who rec ...  Afficher plus

In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific anti ...  Afficher plus

This week’s episode is part 2 of our plasma cell dyscrasias series. We will go over the important details on risk stratification, as well as initial and relapse treatment options for Multiple Myeloma, with key details on the pharmacology of myeloma drugs.